PolyPeptide Group (PPGN) H2 2024 earnings summary

Executive summary

• Achieved substantial improvements in profitability and cash flow in 2024, with strong commercial revenue growth driven by increased demand, phase III project approvals, and a focus on execution and capacity expansion.

• Metabolic business revenue more than doubled over three years, with a 29% CAGR, and commercial business now represents about two-thirds of total revenues, up from 41% three years ago.

• EBITDA margin rose by 9.4 percentage points to 7.5%, reflecting operational gains and product mix changes.

• Advanced capacity expansion with EUR 87.8 million CapEx (26.1% of revenue), preparing for future growth and large-scale GLP-1 contract support.

• Confirmed mid-term outlook to double 2023 revenues by 2028 and reach an EBITDA margin of 25%.

Financial highlights

• 2024 revenue reached EUR 336.8 million, up 5.1% year-over-year; underlying growth (excluding COVID) was 7.1%.

• Commercial revenue surged 31.8%, while development revenue declined by EUR 36.3 million due to project transitions.

• EBITDA improved from EUR -6.0 million in 2023 to EUR 25.4 million in 2024; margin rose from -1.9% to 7.5%.

• Net result improved to EUR -19.6 million from EUR -51.4 million.

• Operating cash flow more than doubled to EUR 89.4 million, driven by profitability and advance payments; free cash flow turned positive at EUR 2.4 million.

Outlook and guidance

• 2025 revenue guidance targets 10%-20% growth, driven by ramp-up of new large-scale capacity and commercial contracts.

• CapEx expected at 15%-20% of revenues in 2025; EBITDA margin to improve year-over-year, with continued focus on operational excellence.

• 2028 outlook confirmed: aim to double 2023 revenues and approach 25% EBITDA margin.